Francisco
Gómez Veiga
Publicaciones (128) Publicaciones de Francisco Gómez Veiga
2024
-
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)
European urology oncology, Vol. 7, Núm. 5, pp. 1051-1060
-
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis
European urology oncology, Vol. 7, Núm. 4, pp. 860-869
2023
-
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial
European urology oncology, Vol. 6, Núm. 1, pp. 58-66
-
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
European Urology, Vol. 84, Núm. 2, pp. 229-241
2022
-
Advances in Urologic Oncology “OncoUrology Forum Special Edition”: The best of 2020
Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 214-222
-
Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice: ANALUTS study
Neurourology and Urodynamics, Vol. 41, Núm. 8, pp. 1824-1833
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282
-
Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Journal of Clinical Oncology, Vol. 37
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups
Prostate, Vol. 82, Núm. 13, pp. 1237-1247
2021
-
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11
European urology oncology, Vol. 4, Núm. 1, pp. 49-55
-
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371
-
La vigilancia activa en pacientes con cáncer de próstata localizado. Análisis de adherencia y salida del protocolo
Archivos espanoles de urologia, Vol. 74, Núm. 5, pp. 477-487
-
Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys
Value in Health, Vol. 24, Núm. 11, pp. 1676-1685
-
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
Targeted Oncology, Vol. 16, Núm. 3, pp. 357-367
-
Reply by Authors
The Journal of urology, Vol. 205, Núm. 5, pp. 1371
2020
-
Advances in urologic oncology “OncoForum”: The best of 2019
Actas Urologicas Espanolas, Vol. 44, Núm. 9, pp. 586-596
-
Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry
Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 156-163
-
Efficacité de l’enzalutamide (ENZA) + traitement par suppression androgénique (TSA) dans le cancer de la prostate hormonosensible métastatique (mHSPC) en fonction de la localisation des métastases : analyses post-hoc de l’étude ARCHES
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 745
-
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
Targeted Oncology, Vol. 15, Núm. 3, pp. 301-315
-
The impact of time from biopsy to radical prostatectomy on Gleason score undergrading and other related factors
Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 187-195